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Intrinsic apoptosis pathwayApoptosis is essential in the death process induced by Amyloid-β (Aβ), a major constituent of diffuse plaques
found in Alzheimer's disease patients. However, we have found that caspase activation and cell death induced
by staurosporine, employed to induce the intrinsic mitochondria-dependent apoptotic pathway, were signiﬁ-
cantly reduced by 42 amino-acid Aβ42, implying that the peptide also has a negative effect on the apoptotic pro-
cess. The inhibitory effect of Aβ42 on the apoptotic pathway is associated with its interaction with procaspase-9
and consequent inhibition of Apaf-1 apoptosome assembly. We detected the inhibitory effect in the early stage
(b8 h) of apoptosis, but later caspase activation becomes obvious. Thus we inferred that the inhibitory process
on apoptosis begins at an early stage, and the later robust activation surpasses it. We propose that the apoptotic
manifestation in Aβ-treated cells is a combined consequence of those anti- and pro-apoptotic processes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Amyloid-β (Aβ) is 36–43 amino acid-long peptides produced by the
sequential proteolysis of the amyloid precursor protein by α-, β- and γ-
secretases [1–4]. The spontaneous conformational changes of the native
Aβpeptides formβ-sheet-rich intermediate structures. The intermediates
are unstable and interact with each other to form aggregates such as
oligomers, protoﬁbrils andﬁbrils [5–7]. The formation of those aggregates
is important and critical to determining cell fate. A leading hypothesis has
been postulated that the progressive deposition of the aggregated Aβ
peptides in brain parenchyma and cerebral blood vessels leads to the neu-
rodegenerative disorder, Alzheimer's disease (AD) [8]. Recent studies,
however, suggest that soluble Aβ42 oligomers and protoﬁbrils formed
during Aβ ﬁbrillogenesis are more toxic than the monomeric species
and ﬁbrils [5,7].genase; ACE, cells treated with
o c, cytochrome c; ΔC, caspase-
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ights reserved.How Aβ leads to cell death is a key question in understanding the
underlying pathology associated with AD. Aβ interacts with a number of
other proteins as exempliﬁed in a recent proteomic analysis for artiﬁcial
β protein and Aβ interactor [9]. The report indicated that amyloidogenic
aggregation can result in the sequestration of numerous proteins such
as translation initiation factors, chromatin regulators, RNA processing
proteins, mitochondrial membrane proteins and chaperones. It is certain
that the sequestration of essential proteins results in cell death.
Besides the sequestration, Aβ can directly induce cell death by binding
to receptors such as the p75neurotrophin receptor, amember of the TNF-
receptor superfamily, which in fact induces cell death [10,11]. Further-
more, interaction with some intracellular Aβ-binding proteins such as
alcohol dehydrogenase (ABAD) and cytochrome c (Cyto c) oxidase also
induces cell death [12,13]. This interaction was shown to result in free-
radical generation in neurons, suggesting direct molecular link from Aβ
to mitochondrial toxicity [14]. Further, the mitochondrial dysfunction
and synaptic damage induced in Aβ-treated cells results in the loss of
mitochondrial membrane potential and increase in mitochondrial super-
oxides [15]. As a result, Bax protein increases and Cyto c is released from
mitochondria. Aβ also seems to induce a signal transduction pathway as
shown in the increase of c-Jun N-terminal kinase activity, which is associ-
ated with cell death pathway such as apoptosis [16].
Although it is not known which type of death process plays a major
role in Aβ-induced cell death, involvement of apoptosis in the process
has been proposed, because caspases are activated upon administration
of the peptide to cells [17–20]. A number of reports indicate that both
caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway) are
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neurotrophin receptor can trigger the extrinsic pathway, while and the
mitochondrial dysfunction caused by the peptide can trigger the intrinsic
pathway. Besides the two apoptotic pathways, caspase-4-mediated apo-
ptosis is also induced by the unfolded protein response signaling pathway
when endoplasmic reticulum stress involved in neurodegenerative
disease including AD is prolonged [22].
Intrinsic mitochondria-dependent apoptosis is characterized by for-
mation of a multiprotein complex called an apoptosome consisting of
Apaf-1, Cyto c, dATP and procaspase-9 after release of Cyto c from mito-
chondria [23]. The formation of this protein complex is essential for
intrinsic apoptosis and is tightly regulated in healthy cells in which Cyto
c is stored in mitochondria and the intracellular concentration of K+ is
high (~150 mM) enough to inhibit the apoptosome formation [24]. It is
also regulated by other proteins such as heat shock protein 70 which
binds to Apaf-1 and prevents the formation of the multiprotein complex
[25]. The formation of the apoptosome leads to activation of caspase-9
which proteolytically cleaves caspase-3 for activation [26].
In the present study, we planned to explore molecular events in the
intrinsic pathway activated in cells with Aβ. Unexpectedly, however, we
found that 42 amino-acid Aβ (Aβ42) can inhibit caspase activation
induced by staurosporine (STS), employed to induce intrinsic apoptosis,
while we were examining the effect of Aβ42 on the activation of caspase
related to the apoptotic pathway. This unprecedentedobservation implies
that Aβ42 can function as anti-apoptotic agent unlike the previous stud-
ied cytotoxic and pro-apoptotic nature of this peptide. In the current
study, we probe the mechanism of how the Aβ42 peptide can lead to
inhibition. First, we sought to uncover which steps of the intrinsic path-
way are negatively inﬂuenced by Aβ42. Second, we searched for pro-
tein(s) related to the inhibitory effect of Aβ42 to understand the related
mechanism, because biological responses are often due to interactions
with other proteins, as mentioned above. Based on the results we suggest
that interactions of the peptidewith other proteins inﬂuence apoptosis in
a different way (for example, negatively as will be shown in this study)
rather than activating it.
2. Materials and methods
2.1. Preparation of Aβ peptide and proteins
Aβ peptide was prepared as previously described [27]. After
monomerization by solubilization in 1,1,1,3,3,3-hexaﬂuoro-2-propanol,
it was dried under a ﬂow of nitrogen and then, under vacuum for
30 min and stored at−20 °C until use. For the experiments, the peptide
was dissolved in 0.1% NH4OH at a concentration of 2 mg/mL followed by
bath-sonication for 10 min. The solution was diluted to desired concen-
trations in phosphate-buffered saline (PBS) or in culture media. Aβ42
oligomers and ﬁbrils were prepared and the aggregation states were de-
termined as previously described [28,29]. Recombinant caspases were
puriﬁed as previously described [30].
2.2. Cell culture and preparation of cell extract
Humanepithelial HeLa and osteosarcomaMG63 cellswere cultured in
Dulbecco's Modiﬁed Eagles medium (high glucose), supplemented with
10%(v/v) fetal bovine serum (FBS) and 1% antibiotics, at 37 °C under 5%
CO2, while neuroblastoma SH-SY5Y was cultured in Dulbecco's Modiﬁed
Eagles medium and Ham's F12 (1:1). The cell extracts were prepared as
described before [24].
2.3. Caspase activity measurement and cell death assay
Catalytic activity of puriﬁed caspase-3 and caspase-3-like DEVDase
was measured in cell extracts prepared from cells treated as indicated in
caspase assay buffer (20 mM Hepes-NaOH, pH 7.0, 20 mM NaCl,
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA and 10 mM dithiothreitol)using 10 μM Ac-DEVD-AMC [30]. Activities of puriﬁed caspase-8 and -9
(NC-pc9, C9 and ΔC in Fig. 7) in the absence or presence of Aβ42 were
similarly assayed using 50 μM Ac-IETD-AMC or 50 μM Ac-LEHD-AMC,
respectively. The ﬂuorescence of the AMC release from the substrates
was measured as described previously [24]. Activity was determined
from the initial velocities of substrate hydrolysis. Cell viability assessed
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) reduction assay was measured as described earlier [24].
2.4. Analysis of Cyto c release
Cells were harvested, washed with ice-cold PBS and resuspended in
digitonin buffer (75 mM NaCl, 1 mM NaH2PO4, 8 mM Na2HPO4,
250 mM sucrose, 190 μg/ml digitonin). After 5 min on ice, the cells
were spun for 5 min at 14,000 rpm at 4 °C in amicrocentrifuge. Superna-
tants were transferred to fresh tubes and the pellets were resuspended in
buffer containing 25 mM Tris–HCl, pH 8.0, and 1% Triton X-100. Equal
amount of proteins from each sample were subjected to sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) andwest-
ern immunoblot assay as described before [24].
2.5. Size exclusion chromatography (SEC) analysis of Apaf-1 apoptosome
assembly and interaction of puriﬁed caspase-9 and Aβ42
For analysis of apoptosome assembly, cell extracts prepared fromeach
treatmentwere subjected to SEC following the procedure described earli-
er [24]. Brieﬂy, 0.9–2 mg cell extract was loaded onto a Superose 6 HR
(10/30) column (Amersham Pharmacia Biotech, Uppsala, Sweden) and
0.5 ml fractions were collected at a ﬂow rate of 0.2 ml/min. Proteins in
the fractions were analyzed by western blot analysis. Interaction of
puriﬁed caspase-9 [NC-pc9, caspase-9 and ΔC, [30]] with Aβ42 was also
analyzed by Sec. 10 μg of each protein incubated with or without 20 μM
Aβ42 for 1 h at 30 °Cwas fractionated as above and the collected fractions
were analyzed by immunoblot analysis for caspase-9 and Aβ. In both
cases, the columnwas calibratedwith calibration kits that included thyro-
globulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), and aldolase
(158 kDa).
2.6. Cell-free system for in vitro apoptosis
DEVDase activity was induced by incubating the cell extracts with
1 mM dATP and Cyto c at the indicated concentration in buffer H
(20 mM HEPES-KOH, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl2,
2 mM DTT, 30 mM KCl) for 1 h at 30 °C [24]. For the analysis of
apoptosome assembly, the extract (2 mg) was reacted with 1 mM dATP
and 10 μg/ml Cyto c for 1 h at 30 °C in buffer H supplemented with addi-
tional 1 mM MgCl2, 0.1% CHAPS and 10% glycerol. DEVDase activation
without the apoptosome formation was also induced by active recombi-
nant caspase-9 (1 μg) instead of dATP/Cyto c.
2.7. Western blot, immunoprecipitation, immunocyto- and immunohisto-
chemistry analysis for interaction of Aβ42 with procaspase-9
Western blot and other immunoassay analysis were performed using
the following antibodies. Monoclonal antibodies to Cyto c, caspase-3,
Apaf-1, caspase-9, DFF-45, caspase-8, anti-amyloid beta (6E10), heat
shock protein 70 and actin were purchased from AB Frontier (Seoul,
Korea), Santa Cruz biotechnology (Santa Cruz, CA), R & D systems (Min-
neapolis, MN), Medical & Biological Laboratories (Nagoya, Japan), Trans-
duction laboratories (Lexington, KY), Cell Signaling Technology, Signet
Laboratories (Dedham, MA), AB Frontier (Seoul, Korea) and Santa Cruz
biotechnology (Santa Cruz, CA), respectively. Polyclonal antibodies to
capase-9 (p10, detecting the small subunit of the enzyme) and serum
containing anti-mouse immunoglobulin were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibody against Bid
was generated by injecting mice with puriﬁed recombinant Bid. Alexa-
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conjucated chicken anti-rabbit IgG antibodies were purchased from
Jackson Immunoresearch Laboratories (West grove, PA).
Immunoprecipitation was performed for ACE and SACE as previously
described [31]. For immunocytochemistry study, cells were seeded in
12-well plates at 70% conﬂuence, cultured for 24 h and further incubated
for 12 h in serum-free medium and then treated as indicated. Harvested
cells were ﬁxed inmethanol at−20 °C and permeabilized by 0.3% Triton
X-100. After blocking with 0.1% BSA overnight, mouse anti-amyloid beta
(6E10) and rabbit anti caspase-9 antibodies (dilution, 1:100) (speciﬁc
for small subunit of caspase-9) were added and incubated overnight at
4 °C. After washing with PBS, Alexa-Fluor-488-conjugated chicken anti-
mouse IgG and Alexa-Fluor-543-conjugated chicken anti-rabbit IgG
antibodies (dilution, 1:200) were treated for 2 h at room temperature
followed by PBS washing. Nuclei were stained with DAPI in Vectashield
mounting medium (Vector Laboratories, California, USA). Confocal im-
ages were obtained with a Carl Zeiss LSM510 microscope (Jena,
Germany) using the vendor-provided software (LSM510).
For immunohistochemistry, desiccated brain tissue of the cortex area,
taken from the human Swedish mutant amyloid precursor protein
(huAPP695.K670N/M671L) transgenic Tg2576 mice [32], were blocked
with OCT cryo embedding media and 12 μm thick frozen brain sections
were prepared by frozen microtome. The sections were ﬁxed, stained
and imaged as described earlier [33].3. Results
3.1. Aβ42 inhibits activation of DEVDase
In the current study, we initially explored apoptotic consequences
such as activation of caspases, formation of the Apaf-1 apoptosome, and
cell death in several lines of cells treatedwith Aβ42 peptides under differ-
ent conditions, in order to probemolecular events of the intrinsic apopto-
sis pathway associated with Aβ treatment. We consistently observed
activation of caspases upon Aβ42 treatment, although the level varied
according to cell types and treatment condition and was often limited
(see below).
Caspase-3-like DEVDase activity was chosen as an apoptosis reporter
in initial study, because it is speciﬁc for activation of apoptosis and a
large number of samples could be examined relatively easily and accu-
rately. Two- to three-fold activation of caspase-3-like DEVDase activity
was noticed in human epithelial HeLa cells incubated with Aβ42 for
24 h (Fig. 1b). To observe this activation, 12 h or more of incubation
was required (Fig. 1). The induced activity is lower than those by other
apoptotic agents such as STS,which inducedmore than 5 times activation
(see Fig. 2a and b). The level of DEVDase activity plateaued or was often
reduced at higher concentrations of Aβ42 (Fig. 1b). A similar pattern of
activation was also observed in human osteosarcoma MG63 cells andAβ42  (µM)
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Fig. 1. Activation of DEVDase by Aβ42. DEVDase activities were measured with 10 μM ac-
DEVD-AMC in HeLa cells treated with mono- or oligomerized Aβ42 at the indicated con-
centrations for 8 h (a) or 24 h (b). The results are the mean ± s.d. of three independent
experiments.neuroblastoma SHSY5Y cells, although the level of activation was even
less in the latter case (data not shown).
We also tested the effects of Aβ42 on caspase activation induced by
STS, a broad spectrumprotein kinase inhibitor and apoptotic agent induc-
ing the intrinsic apoptosis pathway [24]. An additive effect of the peptide
on the activation of the enzyme was expected if the peptide induces the
pathway strongly. Treatment of HeLa cells with STS results in activation
of DEVDase activity, as expected (Fig. 2a). It was unexpected, however,
that concurrent addition of Aβ42 with STS led to a signiﬁcant reduction
in the activation (Fig. 2a). An inhibitory effect of the peptide was also
observed in MG63 cells treated with STS (Fig. 2b). The oligomeric prepa-
ration of Aβ42 was a more effective inhibitor than the monomerized
peptide (Fig. 2a and b) in both cell lines. Fibrillar formof the peptide bare-
ly showed this effect (data not shown). Only Aβ42, not Aβ40, was effec-
tive for inhibition (data not shown). Meanwhile, the inhibitory effect
was relatively weak in SHSY5Y cells, with less than 50% inhibition
observed even in the presence of Aβ42 at as much as 70 μM (Fig. 2c),
implying the inhibitory effect is cell type-speciﬁc. Next, HeLa cells were
primarily explored with oligomerized Aβ42 unless otherwise indicated;
since the inhibitory effect was clearly seen in the cells treated with the
oligomeric form of peptide (see Fig. 2).
Pre-incubation of the cells with Aβ42 peptide prior to STS treatment
was necessary for observation of the inhibitory effects, which varied
signiﬁcantly based on the pre-incubation time (Fig. 2d). The highest
level of inhibition (nearly 80%) was observed in the cells pre-incubated
for 2 h or more with 40–100 μM of Aβ42.
Cell death induced by STS was also suppressed by Aβ42 in a dose-
dependent manner as assessed by an MTT reduction assay (Fig. 2e).
40 μM Aβ42 inhibited cell death as effectively as 20 μM z-VAD-fmk, a
pan-caspase inhibitor. The caspase inhibitor rarely affected the level of
cell death in the presence of 40 μM Aβ42 (Fig. 2e), indicating that these
two agents exert their inhibitory effects on cell death through a common
pathway (i.e., inhibition of caspase activation).
3.2. Aβ42 inhibits Apaf-1 apoptosome formation
In the following experiment, we searched for the step(s) of the intrin-
sic pathway affected by Aβ42. STS was again employed to induce the
pathway characterized by release of Cyto c from mitochondria which is
followed by activation of the caspase-9, -3, and -8 cascade via formation
of the Apaf-1 apoptosome [24]. Cyto c was recovered in the cytosolic or
soluble fractions of the cells incubated with STS within 6 h as expected,
while Aβ42 at concentrations up to 40 μM neither induced the release
of the protein nor affected the release induced by STS (Fig. 3a). The results
also exclude a possibility that the peptide would attenuate the effect of
STS by sequestering it from the solution. The addition of Aβ42 at 70 μM
resulted in a slight decrease in Cyto c level in the soluble fraction
(STS + 70 μM Aβ42 in Fig. 3a). Thus, in the following experiments, less
than 40 μM of Aβ42 were used to explore the effect of the peptide on in-
trinsic cell death processes after Cyto c release. In contrast to the consis-
tent release of Cyto c, the processing of procaspase-9, -3, -8 and their
substrate proteins, DFF45/35 and Bid was signiﬁcantly reduced in the
presence of Aβ42 (Fig. 3b–f). These results suggest that Aβ42 exerts an
inhibitory effect on a step between Cyto c release and procaspase-9
activation.
Therefore, we next explored the effect of Aβ42 on Apaf-1 apoptosome
assembly. For these experiments, we fractionated the extracts prepared
from untreated HeLa cells (HCE) or cells treated with 20 μM Aβ42
(ACE), STS (SCE), and STS plus 20 (SACE) or 40 μM Aβ42 (SACE′) using
SEC as previously described [24] and then compared the elution proﬁles
by probingApaf-1 and caspase-9 in the fractions. InHCE andACE, thema-
jority of Apaf-1 and caspase-9 eluted as single peaks (fractions 28–32 and
29–32, respectively), corresponding to their monomeric forms (Fig. 4a
and b). In SCE, a signiﬁcant amount of the two proteins was recovered
in earlier fractions (#17–22) (Fig. 4c), indicating formation of the
apoptosome complex [24]. On the other hand, they were not detected
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Fig. 3. Effect of Aβ42 on proteins involved in the intrinsic apoptosis pathway. Cyto c re-
lease, processing of caspases, DFF and Bid were assessed by western immunoblot analysis
in HeLa cells incubated with oligomerized Aβ42 for 2 h and further incubated with the
peptide for 6 h in the presence or absence of STS. Actin is employed as a loading control.
The relative molecular weights (in kDa) are indicated at the right. Data are representative
of at least three independent experiments.
688 M.G. Sharoar et al. / Biochimica et Biophysica Acta 1843 (2014) 685–693in the earlier fractions (b#28) in SACE′ (Fig. 4e). These data imply that
Aβ42 negatively inﬂuences apoptosome formation. Intriguingly, in SACE
caspase-9 was not detected in the early fractions as in SACE′, while
Apaf-1, in a reduced amount, was found in the fractions (Fig. 4d). Apaf-
1 recovered in the early fraction is probably a part of a protein complex
lacking caspase-9 (designated as complex I hereafter) [34]. Cells for
SACE were treated with a decreased amount of Aβ42 than for SACE′,
which may allow formation of the complex.kDa 669 440 232 150
Apaf-1
Casp-9 
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Fig. 4. Negative effect of Aβ42 on formation of Apaf-1 apoptosome. The SEC fractions ob-
tained from each cell extract (1–1.5 mg) were analyzed by western blot for Apaf-1 and
caspase-9. The relative molecular weights (in kDa) are indicated to the right or above
the elution fractions.
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To investigate the mechanism through which Aβ42 inhibits apopto-
some formation, we searched for any potential differences between HCE
and ACE. First, activation of DEVDase was compared in the two cell ex-
tracts treated by dATP/Cyto c [24]. A Cyto c dose-dependent activation
was detected in ACE but it was signiﬁcantly lower than that in HCE
(Fig. 5a). Consistently, lower levels of processing of procaspase-9 and -3
were observed in ACE (Fig. 5b).
SEC fractionation of HCE treatedwith dATP/Cyto c and the subsequent
analysis showed that most Apaf-1 and a signiﬁcant amount of processed
caspase-9 was eluted in fractions 13–25, corresponding to the apopto-
some (Fig. 5c). In the same experiment with ACE, a lower amount of
Apaf-1 was recovered in the fractions (#13–25). While caspase-9 was
barely seen in the fractions and recovered primarily as the unprocessed
form only in later fractions (#30–33) where free caspase-9 was detected
(Fig. 5c). It is likely that a protein complex containing Apaf-1 but not
caspase-9, probably the complex I shown in SACE (Fig. 4d), was formed
in ACE treated with dATP/Cyto c. The apoptosome formation containing
procaspase-9, however, is essential for DEVDase activation observed in
ACE (Fig. 5a). We infer that it was formed in the ACE upon treatment of
dATP/Cyto c, though it is invisible in the ﬁgure, probably because its
amount was limited or it became more unstable in the presence of
Aβ42. In sum, the results of the cell-free experiments indicate that ACE
is defective in apoptosome formation, supporting a hypothesis that
Aβ42 exerted its inhibitory effect by affecting intracellular factor(s)
necessary for apoptosome assembly.0
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for 1 h with 1 mMdATP and 1 μMof Cyto c, and then DEVDase activity wasmeasured in the pre
by puriﬁed caspase-9 (1 μg) instead of dATP/Cyto c in HCE or ACE (100 μg). The results of a, eIt is possible that the inhibitory effect of Aβ42 on the apoptosome
assembly might involve indirect processes. For example, the peptide
could induce expression of heat shock protein 70 which binds to Apaf-1
and prevents the formation of the multiprotein complex [25]. However,
no signiﬁcant changes in the levels of the protein were detectable in
ACE or SACE prepared from cells treated with varying concentrations of
Aβ42 (Fig. 5d). The inhibitory effect would be also seen if Aβ42 blocks
K+ efﬂux [24]. Thus, cell-free experiments were further performed to
ask if Aβ42 directly affects apoptosome assembly and activation of
caspase-3. For the experiments we attempted to prepare oligomeric
Aβ42 at concentrations higher than 100 μM used in the above cell
experiments. However, aggregation and precipitation occurred very rap-
idly when preparing the oligomers. Furthermore, an independent study
indicated that oligomeric andmonomeric peptides at low concentrations
resulted in no signiﬁcant differences in the effectiveness in the cell-free
experiment (data not shown). Thus, we employed the monomeric pep-
tide in this and following cell-free experiments. Activation of DEVDase
inHCE treated by dATP/Cyto cwas inhibited in a dose-dependentmanner
by Aβ42 added directly to the cell extract (Fig. 5e, closed circles), suggest-
ing a direct effect of Aβ42 on apoptosome assembly and further
supporting the hypothesis of a negative effect of the peptide on the intrin-
sic pathway. The inhibitory effect was also observed in the extract pre-
pared from SHSY5Y cells (closed triangles of Fig. 5e, see also Fig. 2c for
comparison). Furthermore, it was found that Aβ40 effectively inhibited
the DEVDase activation (Fig. 5e, open circles).
On the other hand, DEVDase activity, once induced by dATP/Cyto c in
HCE, was not suppressed by Aβ42 added to its assay mixture (Fig. 5e,-47
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comparable to that of ACE (Fig. 5f). Thus, we conclude that Aβ42 did
not affect the downstream processes after caspase-9 activation.3.4. Procaspase-9 binds to Aβ42
One hypothesis for the abated formation of the Apaf-1 apoptosome in
ACE is the interaction of Aβ42with component(s) of the protein complex.
In the immunoprecipitation study to test this hypothesis, procaspase-9, a
component of the protein complex, was found to coimmunoprecipitate
with Aβ42 in both ACE and SACE (Fig. 6a). In an immunocytochemistry
study using Aβ42-treated cells in the presence or absence of STS, it was
observed that the immunoﬂuorescence signals from the anti-caspase-9
and anti-Aβ antibodies overlapped in portions of the confocal images of
the cells (Fig. 6b). The overlapping signals were detected in the periphery
of nuclei in cell treated with Aβ42 only, while in cells treated with both
STS and the peptide they were observed largely in the place of nuclei.a)
b)
Fig. 6.Aβ42 binds to procaspase-9. Binding assays by immunoprecipitation (a), immunocytoche
8 (C8), caspase-3 (C3), and Cyto c (Cc) proteins in ACE and SACE were immunoprecipitated wi
proteins. Soluble (S) or precipitated (P) fractions were subjected to western immunoblot anal
antibody was not effective in immunoprecipitation. The reason for this is not clearly understo
mouse brain tissues (c). Each group of HeLa cells was treated as the cells for HCE (control), S
anti-caspase-9(p10) antibodies were used to detect Aβ (green) and caspase-9 (red) whichwer
respectively. Nuclei were stained with DAPI (blue). Yellow spots indicate colocalization of procThe latter case seems due to damage on the nuclei in cells treated with
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from Tg2576 mice (Fig. 6c) [35]. Taken together these data prove
colocalization of caspase-9 and Aβ42 in both cells and tissue, consistent
with binding of the peptide to the enzyme.3.5. Aβ42 preferentially binds to non-processed procaspase-9
The following investigations focused on probing the signiﬁcance of
caspase-9 prodomain [36] and processing in the interaction between
the protein and Aβ42. For this study we employed various puriﬁed
caspase-9 proteins including a non-cleavable procaspase-9 mutant
(E306A/D315A/D330A, referred to as NC-pc9 in text or PC9 in the ﬁgure)
[30]. NC-pc9 was recovered in fractions 30–36 in SEC (Fig. 7a, the ﬁrst
panel labeled by PC9), while a large portion of the protein, when incubat-
edwith 20 μMAβ42 for 1 h prior to the chromatography, eluted in earlier
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PC9 + Aβ). We therefore conclude that changes of the elution pattern
of NC-pc9 in the chromatography result from interaction between the
two proteins, further supporting the results shown in Fig. 6. It is noted
that bothmonomeric and oligomeric Aβ42 peptides were seen in sample
of Aβ42 incubated without caspase protein (Fig. 7a, the last panel), while
additional oligomeric peptides were detected in PC9 + Aβ sample
(Fig. 7a), although it is not clear whether they are related to binding to
procaspase-9.
In similar experiments with processed caspase-9 (C9 in the Fig. 7a), it
was observed that the protein eluted in the early fractions (#13–28) and
in signiﬁcantly lower quantities compared to those in PC9 + Aβ (Fig. 7a,
the fourth panel labeled by C9 + Aβ), consistent with a lower amount of
C9 binding to Aβ. Accordingly, the dissociation constant (KD) value of the
interaction between Aβ42 and C9 increased (N100 μM) in comparison
with that of NC-pc9 (~0.8 μM), where KD was determined by calculating
the ratio of the protein amounts in fractions 29–39 from the Aβ42-absent
and Aβ42-containing groups in Fig. 7a.
Unlike the two prodomain-possessing caspase-9's, elution of the
enzyme lacking the prodomain (ΔC) was not affected by Aβ42 in the
same chromatography. All ΔC incubated as indicated above with the
peptide was recovered in the later fractions (#32–35) like ΔC incubated
without the peptide (Fig. 7a, the ﬁfth and sixth panels). This result
indicates the importance of the prodomain for interaction of caspase-9
with Aβ42.Aβ42 inhibited the catalytic activity of NC-pc9 in a dose-dependent
manner (Fig. 7b), while the activity of processed caspase-9 was affected
by the peptide only in later incubation time (Fig. 7c), reminiscent of
typical slow binding inhibition [37]. In contrast, ΔC enzyme activity was
persistent even in the presence of Aβ42 (Fig. 7d). Other caspases such
as puriﬁed caspase-3, procaspase-8 (data not shown), and DEVDase
activated by dATP/Cyto c in HCE (Fig. 5e, dotted line) were unaffected
by Aβ42, either. This observation is in strong agreement with idea that
speciﬁc binding of Aβ42 to caspase-9 containing the prodomain is what
leads to inhibition of the catalytic activity. Interestingly, caspase-9 activity
from the partially puriﬁed apoptosome was not suppressed by the pep-
tide (Fig. 7e), although the enzyme contains the prodomain [38]. It is
likely that once the apoptosome complex is formed, Aβ42 cannot interact
with caspase-9 due to unavailability of the free prodomain.
4. Discussion
Apaf-1 apoptosome formation can be inhibited by intracellular pro-
teins such as a chaperone proteinwhich interacts with components com-
prising the apoptosome [25], or extracellular factors as illustrated by K+
channel blockers which negatively inﬂuence efﬂux of the ion [24]. Our
study showed that Aβ42 is highly interactive with non-processed
procaspase-9, likely through the prodomain of the enzyme (Fig. 7a and
b). Since the prodomain is also essential for binding to Apaf-1 to form
the protein complex [26,34,36], Aβ42 certainly competes with the
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the caspase, resulting in inhibition of the apoptosome formation. This is
consistent with intracellular operation of Aβ42 for the inhibitory process
(Fig. 7f for summary), although we could not exclude Aβ42 functioning
extracellularly for it as well.
The peptide, added in the culture medium, should enter into cells to
interact with procaspase-9 (Figs. 6a, b and 7a). Oligomer-enriched
preparations of the peptide showed the most efﬁcient inhibitory effect
(Fig. 2a–b), while the preparation of monomeric Aβ42 was as effective
in the inhibition as that of the oligomeric peptide in the cell-free system
(see comments for Fig. 5). This may be due to themore efﬁcient entrance
of the oligomeric form of the peptide into cells as compared to themono-
meric or ﬁbrillar form [39].
The anti-apoptotic function of Aβ has not been observed before, prob-
ably because it is detected only in a speciﬁc condition, as seen in this
study. The inhibition of apoptosis by Aβ42 was observed with STS
which was treated for relatively short time (b8 h). During that short
time, Aβ42 alone rarely induced the caspase activation (Fig. 1a). We
examined whether a similar treatment with Aβ42 inhibits the activation
of DEVDase induced by other apoptotic agents such as UV but did not
detect any inhibition. This may be because the activation of DEVDase
took more time (N12 h) in cells treated with the apoptotic agents.
When the cells were treated for that long duration, Aβ42 alone induces
Cyto c release (data not shown) and DEVDase activation (Fig. 1). In
other words, Aβ could affect DEVDase activation positively rather than
negatively, if the cellswere concurrently treatedwithAβ and an apoptotic
agent for longer time. We did not consider other agents such as Fas or
TNFα, because those protein agents may interact with Aβ and mislead
conclusion. In the context of this study, STS was an excellent choice to
observe the inhibitory effect of Aβ42, especially on apoptosome forma-
tion, since the chemical induces apoptosis quickly (b6 h) via the well-
deﬁned intrinsic pathway.
Pre-incubation of the cells with the oligomer-enriched preparation of
Aβ42 before treatment with STS was also necessary for the inhibitory
effect to be seen (Fig. 2d). A pre-incubation for 2–6 hwas themost effec-
tive, which may reﬂect the time needed for the intracellular inﬂux of the
peptide or its interaction with cellular component such as caspase-9.
Unless the cells were pre-incubated with Aβ, the death process may
begin by STS before the inhibitory process turns on, for the chemical
induces apoptosis relatively quickly.
In sum, the inhibitory effect of Aβ42 on caspase activation was
observed only in the cells that were pre-incubated with the peptide and
then incubated for the relatively short time. This does not mean that the
inhibition process occurred only in the short time period. It may be
operating continuously throughout the apoptotic insult, but it might be
just difﬁcult to detect because it is masked by the robust activation of
the enzyme. Caspase activation as shown in Fig. 1b becomes detectable
only when the later activation pathway surpasses its inhibition. The low
level of DEVDase activation in cells treatedwith Aβ42 (Fig. 1) may reﬂect
the inhibitory effects functioning throughout the apoptotic process.
One important question here is how the peptide induces the caspase
(or DEVDase) activation shown in Fig. 1b. The enzyme can be activated
through the extrinsic pathway [20]. However, the inhibitory process can
affect not only the intrinsic pathway, but also the extrinsic pathway,
because Apaf-1 apoptosome formation is important for the ampliﬁcation
of the apoptotic signal [40] that is mediated by “crosstalk” between the
two pathways in which caspase-8 cleaves Bid to induce the release of
Cyto c [41]. Thus, reduction of apoptosome formation by Aβ42 can result
in impaired apoptotic signal of both pathways. In fact, we could not detect
caspase-8 activation in Aβ42-treated cells (Fig. 3e and unpublished
results). The peptide could promote other death pathway leading to the
caspase activation and cell death, too. The possibility needs to be explored
further.
Other speculation for the caspase activation is as follows: Aβ42 prefer-
entially interacts with free or unbound non-processed procaspase-9, but
possibly part of the enzyme may escape from the inhibitory interaction.It binds to other proteins such as Apaf-1 or the complex I to form
apoptosome in which it is readily processed because the peptide has a
limited inﬂuence on the enzyme (Fig. 7e). Furthermore, the enzyme can
participate in the formation of other apoptosomes after dissociation
from the protein complex more readily than the unprocessed form
(Fig. 7f for summary) [23,42], for it has lower afﬁnity for Aβ42 (Fig. 7a).
As a result, the apoptotic signal can be transduced to the downstream
step of apoptosis such as activation of caspase-3-like DEVDase. Further
research is necessary to prove this hypothesis.
It is not clear yet how Aβ leads to the onset of the apoptotic cell death
program. Aβ can induce the cell death program directly as illustrated by
binding to a death receptor [10,11] or other proteins such as ABAD [13].
However, it is likely that the apoptotic process induced by Aβ is more
complicated than just those events, because Aβ peptide is prone to inter-
act with a number of metastable cellular proteins [9], and a part of these
interactions could cause an anti-apoptotic process as shown here. Biolog-
ical functions of Aβ peptide other than the neurotoxicity have rarely been
explored, although it is certainly imaginable that the peptide results in
diverse reactions when considering the variety of proteins interacting
with Aβ. If the peptide inﬂuences apoptosis in various ways as shown in
the present study, we also speculated that the ﬁnal consequence of Aβ
toxicity is a result of a combination of the various processes. Therefore,
describing those processes is necessary to understand Aβ-induced cell
death. Our results provide support for the idea that Aβ has diverse roles
in cell death including a negative effect and suggest that Aβ induces the
cell death in a complicated process combining those various effects
(including pro- and anti-apoptosis) rather than one speciﬁc death
pathway.
The inhibitory effect of Aβ42 on DEVDase activation varied by cell
types. It is obvious in HeLa andMG63 cells (Fig. 2a and b), but not clearly
seen in SHSY5Y (Fig. 2c). On the other hand the activation by dATP and
Cyto c and its inhibition by Aβ42 were consistently observed in the cell-
free system regardless of the source of the cell extracts (Fig. 5e). The
difference in the two experimental systems may not be derived from
activation of other apoptotic pathway such as the extrinsic pathway in
SHSY5Y cells treated with STS or Aβ as exempliﬁed in the type I cells
[43], because caspase-8 activation was barely detected in the cells (data
not shown). Although the mechanistic details for the observation are
not understood yet, it is very intriguing, because neurotoxicity is one of
the important characteristics of Aβ-related cell death.Acknowledgements
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